Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

0.63 EUR

-0.63 %

5,614 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-0.63 %
-70.19 %
-69.90 %
-72.24 %
-73.81 %
-67.12 %
-82.49 %
-85.44 %
-82.01 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
74.79M EUR
Turnover
1.25M EUR
P/E (adj.) (25e)
-4.13
EV/EBIT (adj.) (25e)
-4.82
P/B (25e)
-12.51
EV/S (25e)
27,227.14
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
1.50 EUR
Updated
09.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 10.02.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2.3
2026

Extraordinary general meeting '26

4.3
2026

Annual report '25

30.3
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
This is a sharp opinion and, for now, an unproven state of affairs. As I understand it, the diseases studied in Bexmab are all ones where Bex could mechanistically work. Myeloid blasts have high Clever-1 expression. However, encouraging results were mainly obtained in MDS. But here...
9 hours ago
by Clark kent
27
I agree with your post, except for the part above. I apologize if my writing gave the impression that I am belittling the thinking of the forum members. That was definitely not my intention. I have just noticed that Clark’s motives have been suspected and his criticism questioned...
16 hours ago
by Jouko
16
Wow, that’s quite a plot twist, doing a 40m rights issue, although it certainly didn’t come out of the blue. Who would toot their own horn if not themselves. Value creation also occurs in a situation where funding is secured. I argue that Faron has a discount due to funding uncertainty...
10 hours ago
by Rushimato
12
This week, news broke where Moderna shared its views on the FDA’s actions. It was apparently quite exceptional. First, the Phase 3 (P3) arrangements for the influenza vaccine had been agreed upon, and the result was a rejection. If I understood correctly, there were differing views...
12 hours ago
by WilunGi
9
If Juho is to be believed, the whole thing fell apart due to the failure of the Verona study and the resulting delay. It’s unlikely that Clark or anyone else foresaw that. Instead, he has frequently warned about excessive valuations and the general risks associated with biotech companies...
10 hours ago
by Jouko
6
Well, I didn’t say that we would end up in a Bex vs. Bex situation, but considering the goal of the study, a Bex+Aza vs. Ven+Aza setup is just as detrimental. In a study aiming to determine the efficacy of Bex, there can only be one variable, and that is Bex. If the control group...
8 hours ago
by OsakasOssi
5
The company’s interest is what matters. Apparently, Dekkers is still needed, so he still has time – if and when there is no added value, he will likely leave immediately. Now, this market bad will is weighing so heavily on Faron that I bet Jurrian’s best-before date is around the...
9 hours ago
by Jummijammi2
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.